Pliant Therapeutics (PLRX) shares were down almost 50% Monday after the company said it has ended its Beacon-IPF phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis after an independent review found an imbalance in IPF-related adverse events between treatment and placebo groups.
Despite this safety concern, early data showed efficacy on forced vital capacity, the company said.
The study is the first late-stage IPF trial halted due to safety reasons while also demonstrating "strong" efficacy signals, it added.
The percentage of IPF-related adverse events in the active groups was around 10%, similar to the phase 2a Integris-IPF trial; however, the placebo group in Beacon-IPF showed a lower adverse event rate, driving the observed imbalance, according to the company.
Pliant Therapeutics said it will review the full dataset to better understand the benefit-risk profile and may plan new studies with lower doses for pulmonary fibrosis or other diseases, such as liver conditions.
Price: 1.75, Change: -1.69, Percent Change: -49.13
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。